Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211062063> ?p ?o ?g. }
- W4211062063 abstract "Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhage. This is the third update of the Cochrane review first published in 2006.To assess the effects of thrombolytic therapy for acute pulmonary embolism.The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 16 April 2018. We undertook reference checking to identify additional studies.We included randomised controlled trials (RCTs) that compared thrombolytic therapy followed by heparin versus heparin alone, heparin plus placebo, or surgical intervention for patients with acute PE. We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug.Two review authors (JY, QH) assessed the eligibility and quality of trials and extracted data. We calculated effect estimates using the odds ratio (OR) with 95% confidence interval (CI) or the mean difference (MD) with 95% CI. We assessed the quality of the evidence using GRADE criteria.We identified no new studies for inclusion in this 2018 update. We included in the review 18 trials with a total of 2197 participants. We were not able to include one study in the meta-analysis because it provided no data that we could extract. Most of the studies carried a high risk of bias because of high or unclear risk related to randomisation and blinding. Meta-analysis showed that, compared with heparin alone, or heparin plus placebo, thrombolytics plus heparin can reduce the odds of death (OR 0.57, 95% CI 0.37 to 0.87, 2167 participants, P = 0.01, low-quality evidence) and recurrence of PE (OR 0.51, 95% CI 0.29 to 0.89, 1898 participants, P = 0.02, low-quality evidence). Effects on mortality weakened when we excluded from analysis four studies at high risk of bias (OR 0.66, 95% CI 0.42 to 1.06, 2054 participants, P = 0.08). The incidence of major and minor haemorrhagic events was higher in the thrombolytics group than in the control group (OR 2.90, 95% CI 1.95 to 4.31, 1897 participants, P < 0.001, low-quality evidence; OR 3.09, 95% CI 1.58 to 6.06, 1553 participants, P = 0.001, very low-quality evidence, respectively). We downgraded the quality of the evidence to low or very low because of design limitations, potential influence of pharmaceutical companies, and small sample sizes. Length of hospital stay (mean difference (MD) -0.89, 95% CI -3.13 to 1.34) and quality of life were similar between the two treatment groups. Limited information from a small number of trials indicated that thrombolytics may improve haemodynamic outcomes, perfusion lung scanning, pulmonary angiogram assessment, echocardiograms, pulmonary hypertension, coagulation parameters, clinical outcomes, and survival time to a greater extent than heparin alone. However, the heterogeneity of the studies and the small number of participants involved warrant caution when results are interpreted. Similarily, fewer participants from the thrombolytics group required escalation of treatment. None of the included studies reported on post-thrombotic syndrome or compared the costs of different treatments.Low-quality evidence suggests that thrombolytics reduce death following acute pulmonary embolism compared with heparin. The included studies used a variety of thrombolytic drugs. Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause major and minor haemorrhagic events and stroke. More high-quality, blinded randomised controlled trials assessing safety and cost-effectiveness of therapies for pulmonary embolism are required." @default.
- W4211062063 created "2022-02-13" @default.
- W4211062063 creator A5001631757 @default.
- W4211062063 creator A5002698291 @default.
- W4211062063 creator A5005584314 @default.
- W4211062063 creator A5028216952 @default.
- W4211062063 creator A5089024368 @default.
- W4211062063 date "2018-12-18" @default.
- W4211062063 modified "2023-09-30" @default.
- W4211062063 title "Thrombolytic therapy for pulmonary embolism" @default.
- W4211062063 cites W1510542347 @default.
- W4211062063 cites W171739323 @default.
- W4211062063 cites W1826106822 @default.
- W4211062063 cites W1831507053 @default.
- W4211062063 cites W1971162409 @default.
- W4211062063 cites W1978243757 @default.
- W4211062063 cites W1987892547 @default.
- W4211062063 cites W1993443958 @default.
- W4211062063 cites W1994196027 @default.
- W4211062063 cites W1999925356 @default.
- W4211062063 cites W2001027084 @default.
- W4211062063 cites W2008335103 @default.
- W4211062063 cites W2009344499 @default.
- W4211062063 cites W2010093844 @default.
- W4211062063 cites W2011195183 @default.
- W4211062063 cites W2011351675 @default.
- W4211062063 cites W2011611174 @default.
- W4211062063 cites W2011985774 @default.
- W4211062063 cites W2016010643 @default.
- W4211062063 cites W2022993510 @default.
- W4211062063 cites W2024687690 @default.
- W4211062063 cites W2026971812 @default.
- W4211062063 cites W2028916703 @default.
- W4211062063 cites W2032284721 @default.
- W4211062063 cites W2032534148 @default.
- W4211062063 cites W2032902268 @default.
- W4211062063 cites W2033926692 @default.
- W4211062063 cites W2035100900 @default.
- W4211062063 cites W2037890933 @default.
- W4211062063 cites W2039059007 @default.
- W4211062063 cites W2041176958 @default.
- W4211062063 cites W2045352418 @default.
- W4211062063 cites W2047794424 @default.
- W4211062063 cites W2060548555 @default.
- W4211062063 cites W2062216843 @default.
- W4211062063 cites W2062526007 @default.
- W4211062063 cites W2068640936 @default.
- W4211062063 cites W2070796547 @default.
- W4211062063 cites W2071594049 @default.
- W4211062063 cites W2073284581 @default.
- W4211062063 cites W2081071955 @default.
- W4211062063 cites W2081558310 @default.
- W4211062063 cites W2085984247 @default.
- W4211062063 cites W2097350939 @default.
- W4211062063 cites W2100487920 @default.
- W4211062063 cites W2105077761 @default.
- W4211062063 cites W2105361932 @default.
- W4211062063 cites W2107941853 @default.
- W4211062063 cites W2109257283 @default.
- W4211062063 cites W2110112924 @default.
- W4211062063 cites W2117543837 @default.
- W4211062063 cites W2120934774 @default.
- W4211062063 cites W2129593751 @default.
- W4211062063 cites W2131387283 @default.
- W4211062063 cites W2152634120 @default.
- W4211062063 cites W2154760417 @default.
- W4211062063 cites W2159007980 @default.
- W4211062063 cites W2160443953 @default.
- W4211062063 cites W2164268628 @default.
- W4211062063 cites W2169548288 @default.
- W4211062063 cites W2171306117 @default.
- W4211062063 cites W2198153722 @default.
- W4211062063 cites W2236152156 @default.
- W4211062063 cites W2314752424 @default.
- W4211062063 cites W2317651226 @default.
- W4211062063 cites W2341724638 @default.
- W4211062063 cites W2397242753 @default.
- W4211062063 cites W2401024977 @default.
- W4211062063 cites W2406064047 @default.
- W4211062063 cites W2411245419 @default.
- W4211062063 cites W2412322620 @default.
- W4211062063 cites W2412997669 @default.
- W4211062063 cites W2415154607 @default.
- W4211062063 cites W2415263976 @default.
- W4211062063 cites W2415391397 @default.
- W4211062063 cites W2415905987 @default.
- W4211062063 cites W2416113459 @default.
- W4211062063 cites W2431126293 @default.
- W4211062063 cites W2438628416 @default.
- W4211062063 cites W2528078136 @default.
- W4211062063 cites W2541560893 @default.
- W4211062063 cites W2563013569 @default.
- W4211062063 cites W2599324752 @default.
- W4211062063 cites W2677312504 @default.
- W4211062063 cites W2725067550 @default.
- W4211062063 cites W2765106483 @default.
- W4211062063 cites W2774413076 @default.
- W4211062063 cites W2784328675 @default.
- W4211062063 cites W2792529388 @default.
- W4211062063 cites W2808145191 @default.